Promising combo tackles tough head and neck cancers
NCT ID NCT04862650
First seen Feb 15, 2026 · Last updated May 19, 2026 · Updated 15 times
Summary
This study tests a combination of an immunotherapy drug (cemiplimab) and low-dose chemotherapy (paclitaxel and carboplatin) in 46 people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than current treatments. Participants must not have had prior chemotherapy for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.